Dual-targeted therapy with apremilast and vedolizumab in pyoderma gangrenosum associated with Crohn's disease

J Dermatol. 2020 Jun;47(6):e216-e217. doi: 10.1111/1346-8138.15283. Epub 2020 Apr 29.

Authors

Marta Vernero¹, Davide Giuseppe Ribaldone², Caterina Cariti³, Simone Ribero³, Sara Susca³, Marco Astegiano⁴, Paolo Dapavo³

Affiliations

¹ First Department of Internal Medicine, University of Pavia, Pavia, Italy.
² Department of Medical Sciences, University of Turin, Turin, Italy.
³ Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy.
⁴ Unit of Gastroenterology, Molinette Hospital, Turin, Italy.

PMID: 32347562
DOI: 10.1111/1346-8138.15283

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / therapeutic use*
Crohn Disease / complications*
Crohn Disease / immunology
Drug Therapy, Combination / methods
Humans
Male
Pyoderma Gangrenosum / drug therapy*
Pyoderma Gangrenosum / immunology
Thalidomide / analogs & derivatives*
Thalidomide / therapeutic use
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Thalidomide
vedolizumab
apremilast